
## Financial impact of reacquisition of North American rights for RUCONEST®



2017 **Operating Profit** Costs to boost **RUCONEST®** Sales and infrastructure Costs **RUCONEST SOLUTIONS** Costs **Pharming historical** income under Valeant License

2018 onward **Operating Profit** Sales and infrastructure Costs **RUCONEST SOLUTIONS Costs** Pharming historical income under Valeant License

